INTRODUCTION

Bipolar disorder has a high comorbidity rate (40%) with anxiety disorders. Approximately 15% of people with bipolar disorder are diagnosed with panic disorder during their lifetime. The comorbidity of anxiety disorders, especially panic disorder, negatively affects the clinical course of bipolar disorder and is correlated with poor treatment outcomes, a greater risk of suicide, substance misuse, and an earlier age of bipolar disorder onset.

Panic disorder seems to share a genetic susceptibility with bipolar disorder. Patients with bipolar disorder are highly sensitive to anxiety, panic disorder during adolescence is a risk factor for developing bipolar disorder in adulthood, and there is a higher prevalence of panic disorder in first-degree relatives of patients with bipolar disorder than in those of patients with unipolar depression and recurrent depression. Structural and functional neuroimaging studies have revealed a shared pathology between bipolar disorder and panic disorder; for example, the reactivity of a small area of the amygdala increases/decreases during a manic/depressive episode in bipolar disorder. A gray matter volume reduction in the amygdala and its hyperactivity in response to stimuli have also been reported in panic disorder. The amygdala and ventral prefrontal cortex-amygdala network play a key role in mood regulation in bipolar disorder and the regulation of fear and anxiety.

However, studies on treatment for comorbid panic disorder and bipolar disorder are scarce, and treatment guidelines are based on a small number of studies with low levels of evidence. The lack of effective interventions to manage anxiety symptoms may lead clinicians to prescribe more benzodiazepines or patients to self-medicate more (e.g., with alcohol). The treatment of panic symptoms in patients with comorbid bipolar disorder is challenging. Antidepressant treatment, the first-line treatment for panic disorder, is controversial, as it can lead to mood destabilization in patients with bipolar disorder.
disorder. Bipolar disorder patients with panic disorder who take antidepressants have a greater risk of manic switching. The risk of manic switching is especially high in patients showing panic symptoms concomitantly during manic episodes. The Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines recommend quetiapine and gabapentin as first-line treatments for anxiety disorders in patients with bipolar disorder. Valproate, lamotrigine, serotonergic antidepressants, and olanzapine are second-line treatments. Cognitive behavioral therapy (CBT) has been recommended as the first-line treatment for anxiety management in adolescents. However, none of the above treatment options have been shown to be better than others in randomized controlled clinical trials. Although the treatment of panic disorder comorbid with bipolar disorder is clinically important, associated research is lacking.

CBT for panic disorder, developed by Barlow, demonstrates efficacy and is regarded as a first-line treatment for this disorder. An interoceptive fear conditioning model of panic disorder explained that susceptible people (i.e., those with biological vulnerability or stress due to negative life events) experience panic attacks (unconditioned stimulus [US]) incidentally and then later associated with the interoceptive cues (conditioned stimulus [CS]; e.g., physical sensations such as palpitations, shortness of breath, and dizziness) (Table 1). Agoraphobia can also be explained through fear conditioning. Repetitive panic attacks (US) are associated with the contextual situation (CS) in which an attack is experienced. Affected individuals then generalize this association to similar situations, avoid causal situations, and restrict everyday life activities (agoraphobia). In exposure therapy, patients face situations that induce agoraphobia without avoiding them. Exposure therapy with interoceptive and situational exposure is an active component of CBT for panic disorder (Table 1). Recently, attempts have been made in the field of posttraumatic stress disorder (PTSD) to increase the effectiveness of CBT with the help of drugs. Patients with PTSD showed a better response to exposure-based treatment when propranolol was used immediately before the retrieval of traumatic memories.

Based on the similarities in the pathogeneses of panic disorder, agoraphobia, and PTSD, it may be possible to improve CBT through the study of rodent models, such as fear conditioning and extinction training (a rodent analog of exposure therapy). The successful use of antidepressants or propranolol combined with exposure-based therapy in rodent models has been reproduced in clinical studies of anxiety disorders as well as PTSD. Based on these successful translational studies, the fear conditioning model has high predictive validity in relation to anxiety disorders and is a good model for discovering new therapeutic interventions.

Anecdotal evidence suggests that valproate may be an alternative treatment for panic disorder, antidepresant-resistant panic disorder, and panic disorder with comorbid bipolar disorder. However, these initial findings have not been substantiated by subsequent studies. Randomized controlled studies comparing each treatment option with placebos are lacking. Therefore, in clinical guidelines for panic disorder, valproate remains a tertiary adjuvant option with little evidence or it is not mentioned.

Valproate has anxiolytic effects through its promotion of gamma-aminobutyric acid and acts as a histone deacetylase 2 (HDAC2) inhibitor. HDAC2 inhibition has been shown to improve learning and memory by enhancing neural plasticity. Extinction training in combination with valproate facilitates the attenuation of learned fear in rodent models through effective inhibition of HDAC2 by valproate. Moreover, an HDAC2 inhibitor (CI-994) successfully inhibited treatment-resistant remote fear memories in mice. Except for valproate, HDAC2 inhibitors (e.g., CI-994) cannot be applied in the treatment of anxiety disorders, as they have received Food and Drug Administration (FDA) approval only for chemotherapy. Thus, inspired by the synergistic effects of HDAC2 inhibitors and exposure-based therapy in a rodent model of anxiety disorders, the author hypothesized that valproate, a clinically available HDAC2 inhibitor, might enhance the treatment response to CBT in patients with comorbid panic disorder and bipolar disorder.

Here, the cases of three patients with comorbid panic disorder and bipolar disorder treated with valproate adjuvant therapy for CBT are presented. Additionally, the background preclinical research on this combination therapy based on the reconsolidation-updateing mechanism, the inhibition of HDAC2, critical period reopening, off-label use of valproate in panic disorder, plasticity-augmented psychotherapy, and how to combine valproate with CBT is discussed.

### Table 1. Interoceptive conditioning model of panic disorder and agoraphobia

| Variable               | CS                  | US                  | CR                      | Behavioral intervention                  |
|------------------------|---------------------|---------------------|-------------------------|-----------------------------------------|
| Fear conditioning      | Contextual cue      | Foot shock          | Freezing/avoidance      | Extinction                              |
| Panic disorder         | Interoceptive stimulus | Panic attack             | Avoidance/anticipatory anxiety | (Interoceptive) exposure therapy          |
| Agoraphobia            | Situation           | Panic attack         | Avoidance/agoraphobia   | (Situational) exposure therapy           |

CS, conditioned stimulus; US, unconditioned stimulus; CR, conditioned response
CASE SERIES

Case 1: bipolar I disorder, panic disorder, agoraphobia

A woman in her 30s visited our outpatient clinic. At 25 years of age, she experienced her first major depressive episode. After taking antidepressant medications, her mood shifted to a manic episode. While taking medication (lithium 750 mg, lamotrigine 75 mg, and quetiapine 100 mg daily), she attempted suicide twice, including slashing her wrists and attempting to overdose on drugs. The patient stopped taking the medication after experiencing lithium intoxication. She quit her job after the onset of mood symptoms and suffered from panic disorder and agoraphobia. She could not enter crowded cafés or supermarkets because of the fear that others would see her panic attacks. On her first visit, valproate 750 mg, quetiapine 100 mg, and clonazepam 0.25 mg were prescribed because she wanted to take a mood stabilizer other than lithium. To relieve her agoraphobia and regain occupational functionality, she underwent CBT. During the 12 sessions, the patient took the medications mentioned above. The relaxation technique and systematic desensitization to agoraphobia-inducing situations gradually relieved her avoidance of causal activities. Her initial Panic Disorder Severity Scale (PDSS) score was 17; however, after 12 sessions, it decreased to 0 (Figure 1). She no longer took a taxi instead of public transportation to go to the hospital, and she could go out for coffee or enter crowded buildings by herself. She attended a job interview and began to work again. Agoraphobia and panic symptoms had not recurred at the six-month follow-up after CBT completion.

Case 2: bipolar I disorder, panic disorder, generalized anxiety disorder

A woman in her 40s visited our outpatient clinic complaining of recurrent panic attacks. She had a family history of bipolar disorder and experienced postpartum depression with psychotic features at the age of 30. She was diagnosed with bipolar I disorder and prescribed escitalopram 10 mg, alprazolam 1.5 mg, quetiapine 25 mg, and valproate 300 mg, which she took for three years. She was diagnosed with generalized anxiety disorder and panic disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria. Her anxiety symptoms were not alleviated after three years of taking the above medications. She was worried that she might attempt suicide. The patient also exhibited hypochondriasis and somatic symptoms. After careful evaluation, the patient was prescribed a new medication, escitalopram (valproate 500 mg, quetiapine 100 mg, and alprazolam 1.5 mg). She underwent 15 sessions of CBT targeting her panic disorder and generalized anxiety disorder. Compared with the standard 12 sessions of CBT for panic disorder, to teach her how to cope with excessive worry, the proportion of cognitive reappraisal techniques was increased, and the treatment was extended to 15 sessions. Her initial PDSS score was 14, which decreased to 7 after 15 sessions of CBT. At the six-month follow-up, she had symptoms of generalized anxiety but no panic attacks (Figure 1).

Case 3: bipolar II disorder, panic disorder, agoraphobia

A woman in her late 20s visited our outpatient clinic. She had experienced a major depressive episode at 14 years of age. She was diagnosed with panic disorder and agoraphobia in her 20s and had a history of inpatient treatment for major depressive episodes with psychotic features. She failed to maintain her academic and occupational functioning because of depressive symptoms and agoraphobia. Although she had been taking antidepressant medications, including a selective serotonin reuptake inhibitor (SSRI) and norepinephrine dopamine reuptake inhibitor (fluoxetine 20 mg, bupropion SR 150 mg), for more than 5 years, her depressive symptoms had not diminished, and she had attempted suicide. The patient experienced hypomanic episodes during the follow-up peri-
od. The patient was diagnosed with bipolar II disorder. Her medication was changed to quetiapine (400 mg) and lithium (750 mg). However, she still experienced recurrent panic attacks, had trouble using public transportation, and was reluctant to visit crowded places such as supermarkets. Thus, she decided to undergo CBT and completed 12 sessions. Valproate 750 mg was added to her medication regimen during the final five sessions, which encompassed exposure training in agoraphobia-provoking situations. The patient’s PDSS score decreased to 1 from an initial score of 11. After the completion of CBT, valproate was reduced, and her agoraphobia was successfully alleviated. At the 6-month follow-up, her panic disorder and agoraphobia symptoms remained in remission (Figure 1).

DISCUSSION

In these three cases, the combination of valproate and CBT in patients with bipolar disorder who did not respond to previous standard treatments successfully managed panic symptoms and agoraphobia. Agoraphobia, which can be diagnosed alone but is typically accompanied by panic disorder, is a clinical condition associated with poor prognosis in the treatment of panic disorder.48

Comorbid bipolar disorder is also regarded as a poor prognostic factor for the treatment of panic disorder.49 In the three cases above, two patients (cases 1 and 3) had suffered panic disorder with agoraphobia for a long period of time, and none of the patients responded to two or three consecutive trials of pharmacotherapy, including quetiapine combined with valproate (cases 1 and 2) and quetiapine combined with lithium (case 3). In case 2, valproate was used previously, and in case 1, valproate was started when CBT was started; valproate continued to be used in both cases even after CBT was terminated. However, in case 3, because lithium and quetiapine were already being used for maintenance treatment, valproate 750 mg was used only temporarily during CBT; nonetheless, the effect was maintained without the recurrence of ago-

Figure 2. Schematic diagram of valproate adjuvant treatment for CBT. Plasticity-augmented psychotherapy is a framework for understanding the mechanism of action in combined pharmacotherapy and CBT. Activity-dependent neural plasticity is the foundation for adaptation to the environment. Antidepressants, ketamine, and psychedelics, such as MDMA and HDAC2 inhibitors, enhance neural plasticity by modulating neurotransmitters and epigenetic modifications, such as histone acetylation. Critical period-like plasticity not only offers an opportunity to repair developmental impairments in sensory processing but also allows the correction of dysfunctional behavioral symptoms. The reconsolidation-updating paradigm activates a memory engram that supports maladaptive coping behavior in panic disorder and agoraphobia. Consequently, the memory engram becomes malleable to the environment within a limited time window. Therapeutic interventions such as CBT should be provided to patients during this period. CBT, cognitive behavioral therapy; PNN, perineuronal net; PV, parvalbumin interneurons; E/I, excitatory/inhibitory; 5-HT, 5-hydroxytryptamine; NE, norepinephrine; DA, dopamine; BDNF, brain-derived neurotrophic factor; Rc, receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid receptor; NMDAR, N-methyl-D-aspartate receptor; TrkB, tropomyosin receptor kinase B; cAMP, 3',5'-cyclic adenosine monophosphate; MAPK, mitogen-activated protein kinase; PKA, protein kinase A; CaMKIV, calcium/calmodulin-dependent protein kinase type IV; RSK, ribosomal s6 kinase; CREB, cAMP response element-binding protein; CRE, cAMP response element; HDAC, histone deacetylase; MDMA, 3,4-methylenedioxy-methamphetamine; US, unconditioned stimulus; CS, conditioned stimulus.
aphobia or panic disorder for six months after the treatment (Figure 1).

Here, the author reports a case series of successful treatment of panic symptoms and agoraphobia in patients with comorbid bipolar disorder through valproate adjuvant treatment for CBT (Figure 2). However, a few limitations of this study should be mentioned. Mood symptoms, often accompanied by panic symptoms, were not objectively monitored throughout the CBT course in the case series. The serum concentrations of valproate were not determined over the course of treatment. The author previously published a review article that comprehensively explained in detail the theoretical background of combining valproate and CBT. Here, the theoretical background of valproate and CBT is briefly described in the following sections (Figure 2).

Reconsolidation updating and psychological treatment

Memory reconsolidation is a phenomenon observed in various categories of memory, including emotional memory, in both animals and humans and explains the behavioral changes that occur during psychotherapy. The memory is strengthened, weakened, or updated in response to environmental stimuli immediately after memory recall, a process known as memory reconsolidation. The counterpart of memory reconsolidation is memory consolidation immediately following memory acquisition. Memory consolidation and reconsolidation involve shared and distinct cellular, molecular, and synaptic processes.

The amygdala is essential for the formation and recall of emotional memories associated with positive and negative valence emotions, such as fear memory. The formation and recall of these emotional memories occur through unconscious processes. Transference and “working through” in psychoanalysis are good examples of the reconsolidation of emotional memories.

It is difficult to eradicate a fear memory once it is formed. Extinction training, which repetitively presents the CS without US, can only transiently inhibit the expression of fear memory. After time has elapsed, the learned fear re-emerges (spontaneous recovery). However, very young mice are highly resilient in terms of recovery after extinction training, without spontaneous recovery (Figure 3). Chronic antidepressant treatment can rejuvenate neurons in adult mice to eliminate

Figure 3. Preventing the return of fear memories with pharmacological and behavioral interventions. Fear memories are reluctant to be persistently suppressed by extinction. Unlike adult mice, juvenile mice exhibit enhanced neural plasticity to such an extent that their fear memories are erased by extinction. This juvenile-like plasticity can be achieved by various interventions, such as chronic antidepressant treatment, reconsolidation updating, and HDAC2 inhibition. Remote fear memories, which are more difficult to persistently suppress by extinction, can be successfully suppressed by a combination of reconsolidation updating and HDAC2 inhibition. Valproate, a clinically available HDAC2 inhibitor, is known to facilitate the extinction of recent fear memories. Ret, retention (retrieval); FC, fear conditioning; d, day; w, week; h, hour; HDAC, histone deacetylase.
fear memories without causing relapse (Figure 3).29

With no pharmacological intervention, by presenting CS 1 hour before extinction training, a recent fear memory can be successfully erased without spontaneous recovery.57 During the reconsolidation window (10 minutes–6 hours), neurons that participate in the memory engram are activated and malleable in response to environmental stimuli.58 Adequate learning during the reconsolidation period profoundly rewrites the preexisting emotion-associated memory, a process termed “reconsolidation updating.”

This reconsolidation update has been proven to work well in humans when applied to recent fear memories (Figure 3).59-61 However, as in animal experiments, the application to remote fear memories (1 month) was not successful in consistently reducing the fear response.62 The reconsolidation-updating phenomenon is regulated by brain-derived neurotrophic factor (BDNF). BDNF Met variants, which are reported to be associated with low BDNF expression and thus less neuroplasticity, were associated with a non-persistence of these effects.63

This reconsolidation process is an adaptation strategy that allows individuals to modify already-formed behaviors when circumstances change.25 Memories should be both persistent and rewritable and should be regulated by coordinated mechanisms at the synaptic, cellular, and transcription levels.64 Epigenetic modifications, such as histone acetylation and deacetylation, regulate the transcription of target proteins involved in the consolidation and reconsolidation of memory. Increased histone acetylation by histone acetyl transferase in the target gene promoter increases gene expression, whereas decreased histone acetylation through increased HDAC activity decreases the transcription of target genes (Figure 2).

Remote fear memories are less able to be modified after memory recollection than recent fear memories (Figure 3).62 The histone acetylation level after the recall of remote fear memories is significantly less than that after the recall of recent fear memories. Histone acetylation is upregulated by histone acetylases and antagonistically downregulated by histone deacetylases. Pharmacologically, HDAC2 inhibition (by CI-994) has been shown to restore histone acetylation activity to the level of that with recent fear memory recall after memory recall during the reconsolidation window and extinction training and to successfully erase remote fear memories without later relapse (Figure 3).66

**Valproate as an histone deacetylase 2 inhibitor and critical period reopening**

The cellular mechanisms underlying the reconsolidation-updating of remote memory are similar to the regulatory mechanisms involved in reopening critical periods of sensory development. If an appropriate visual stimulus is not given at a critical time, even if visual function is restored later, the visual stimulus cannot be seen. However, amblyopia caused by sensory deprivation of one eye is restored through the recovery of visual stimuli along with the reopening of the critical period with drugs (e.g., antidepressants, valproate, ketamine, and psychedelics) (Figure 2).65,66

Various psychotropic drugs that affect neuroplasticity have been shown to extend or restore critical periods. Chronic antidepressant treatment and ketamine have also been associated with the reopening of critical periods. Moreover, ketamine can restore amblyopia in adult mice.67 However, chronic antidepressants can restore amblyopia in younger mice but not in adult mice.68

The regulatory mechanism of the critical period can be partially explained by the excitatory-inhibitory imbalance hypothesis. The excitatory-inhibitory balance is shifted to a hyperexcitable state through the reopening of the critical period because of decreased GABAergic pathway activity (i.e., through antidepressants and HDAC2 inhibition) and increased excitatory glutamatergic pathway activity (i.e., through ketamine).65 The perineural network, which consists of GABA interneurons, is transformed into an immature form with chronic antidepressant use29 and HDAC2 activity69 and remains relevant to fear conditioning because this structure also exists in the amygdala, hippocampus and prefrontal cortex.70,66

If HDAC2 functions as a molecular brake that suppresses the critical period, it would be reasonable to investigate whether HDAC2 inhibition can promote psychotherapeutic effects related to memory reconsolidation (Figure 2). Amblyopia in adult mice can be restored using valproate to reopen the critical period.70 Valproate was effective in acquiring absolute pitch through training in adults.71 Valproate combined with growth factors restored hearing loss in a rodent model of sensorineural hearing loss.72 HDAC2 inhibition is thought to result in “juvenile-like induced plasticity” in the brain, given that the deletion of HDAC2 prolongs the critical period in the visual cortex of mice.69

Notably, if either of these two factors—critical period reopening and appropriate environmental stimuli—are missing, no restoration of function can be expected. Although several studies have investigated whether valproate has anxiolytic effects,33,37,73,74 whether a combination of CBT and valproate can treat anxiety disorders has not been studied.27

**Off-label use of valproate in panic disorder**

In Korea, owing to off-label use regulations in place since 2010, clinical research on the off-label use of psychotropic drugs has decreased significantly.79 For off-label use research, the Korean Food and Drug Administration (KFDA) requires an investigational new drug (IND) application, which neces-
| Author (year) | Target disorder | Study type | Participants | Dose of valproate | Result |
|---------------|-----------------|------------|--------------|-------------------|--------|
| Primeau et al. 35 (1990) | Panic disorder | Open-label trial | Enrolled, N=10 | Start at 500 mg/days; titration up to max 2,250 mg/day | Significant improvement in CGI-S, HAMA, panic factor of SCL-90 |
| Keck et al. 36 (1993) | Panic disorder | 4 week, open-label trial | Enrolled, N=16; completed, N=14 | Valproate loading dose of 20 mg/kg/day; adjust dose at serum conc. >50 ug/mL | 10 (71%) showed >50% reduction in panic attacks per week; HAS 30.8±9.4 (SD) to 12.6±7 after 4 weeks of treatment; 6 (43%) had complete remission; 10 (83.%) of 12 patients experienced reduced lactate-induced panic symptoms compared to initial lactate challenge |
| Woodman and Noyes 33 (1994) | Panic disorder | 6 week, open-label trial | Enrolled, N=12; completed, N=12 | Start at 500 mg divalproex sodium, titration up according to clinical response and tolerability | Panic attacks and anxiety improved more quickly than phobic avoidance; sustained improvement at 6-month follow-up |
| Baetz and Bowen 38 (1998) | Panic disorder refractory to antidepressant | 8 week, open-label trial | Enrolled, N=13; completed, N=10 | Flexible dose (conc. 45–90 ug/mL) | Panic attack reduction from 8.3±2.5 (baseline) -> 2.6±0.9 (week 8); significant improvement in anxiety, depressive symptoms and quality of life |
| Perugi et al. 37 (2010) | Panic disorder with bipolar disorder or antidepressant-resistance | 3-year, open-label trial | Enrolled, N=35 (panic disorder with bipolar disorder). N=12 (resistant to antidepressant) | Mean dose=687 mg/day (min 400 mg, max 1,500 mg/day) | Adjunctive valproate treatment was well tolerated; 31 of 35 (88.6%) patients with bipolar disorder and 12 of 12 (100%) patients refractory to antidepressant achieved remission; 17 of 35 (48.6%) and 7 of 12 (58.3%) had a relapse of panic disorder in 3 years |
| Bach et al. 73 (2018) | Anxiety | Double-blind, randomized, placebo-controlled trial | Healthy volunteer | Valproate 400 mg, pregabalin 200 mg | Time spent in safe space reduced in valproate and gabapentin compared to placebo |
| Kinrys et al. 77 (2003) | Social anxiety disorder | 12-week open-label/ single blinded | Enrolled, N=17; completed, N=15 | Flexible dose (500–2,500 mg) | LSAS 21.3 reduction (41.1% responders) in all, 19.1 reduction (46% responders) for those who completed the treatment |
| Aliyev and Aliyev 74 (2008) | Generalized anxiety disorder | 6 weeks, double-blind, randomized, placebo-controlled trial | Valproate group: enrolled, N=40; completed, N=36; placebo: enrolled, N=40; completed, N=38 | Valproate (depakine chrono) 1,500 mg/day divided by three times | Valproate group (HAS 20.0±4.2) showed significantly less anxiety than placebo group (27.0±3.5) at week 6; 26 of 36 depakine chrono-treated patients responded by 6 weeks; 6 of 38 placebo-treated participants responded |

CGI-S, clinical global impression-severity; SCL-90, symptom checklist-90; HAS, Hamilton Anxiety Scale; LSAS, Liebowitz Social Anxiety Scale; SD, standard deviation
showed clinical effects in patients with social anxiety disorder,\textsuperscript{37} and antidepressant-refractory panic disorder.\textsuperscript{37} Therefore, Korean researchers are faced with a dilemma, as the lack of clinical evidence required research, but clinical evidence was required to obtain approval to perform off-label research.

Only five open-label studies have shown promising results in treating patients with panic disorder,\textsuperscript{33,35,36} panic disorder with comorbid bipolar disorder,\textsuperscript{37} and antidepressant-refractory panic disorder (Table 2).\textsuperscript{37,38} Even when the search was widened to include anxiety disorder only, one double-blind, placebo-controlled randomized study reported positive results for generalized anxiety disorder.\textsuperscript{74} One open-label study showed clinical effects in patients with social anxiety disorder.\textsuperscript{77} Furthermore, as there were positive results in only three open-label studies regarding panic disorder, it is difficult to conduct an off-label clinical study with the approval of the KFDA in Korea. To circumvent these obstacles, it is imperative to build evidence to apply valproate adjuvant therapy for CBT for the treatment of panic disorder with comorbid bipolar disorder.

Valproate has been investigated as an alternative to benzodiazepines for anxiety treatment. Valproate 500 mg showed anti-anxiety efficacy in a placebo-controlled randomized study using a computer game designed to test incentive-based risk-taking behaviors and risk-avoidance tendencies in healthy volunteers (Table 2).\textsuperscript{34} Unlike benzodiazepines, patients do not develop tolerance to valproate.\textsuperscript{78} Furthermore, one study reported a therapeutic effect when a mood stabilizer was administered to patients with anxiety disorders who did not respond to conventional anti-anxiety treatment.\textsuperscript{74} Thus, panic disorders that do not respond to antidepressants may be related to a predisposition to bipolar disorder. The effect of valproate facilitated extinction in a preclinical fear conditioning model (Figure 3).\textsuperscript{44,45}

Plasticity-augmented psychotherapy

Psychedelic drugs have recently gained increasing attention in psychiatry. Psilocybin-assisted psychotherapy shows promises in the treatment of major depressive disorders\textsuperscript{79} and PTSD.\textsuperscript{80} Ketamine is attracting attention as a treatment for treatment-resistant depression\textsuperscript{81} and suicidal ideation.\textsuperscript{82} The mechanisms of these psychedelic and conventional psychoactive drugs converge into enhanced neuroplasticity involving neurotransmitters, neurotrophic factors, and epigenetic modifications (Figure 2).\textsuperscript{57,63} These psychedelic drugs affect neuroplasticity with even higher potency than conventional antidepressants.\textsuperscript{65,64}

Beyond the extensive attention, although efficacy has been demonstrated in well-designed randomized controlled trials for severe refractory major depressive disorder and PTSD,\textsuperscript{79,80} psychedelic drugs are designed for use only in severely refractory patients during very limited sessions by certified psychotherapists, and there is a risk of substance abuse and uncertainty regarding long-term consequences.\textsuperscript{83}

From this perspective, the author believes that investigations as to whether valproate, which has been used in clinical practice for a long time and is free from the risk of drug abuse, is effective in enhancing the effects of CBT should be a priority.

How to combine valproate with cognitive behavioral therapy

The optimal dosing strategy for using valproate during CBT remains unknown. The serum concentration of valproate should be at least 36 μg/mL for mild HDAC2 inhibition and 72–120 μg/mL for strong HDAC2 inhibition.\textsuperscript{46} The therapeutic range (50–100 μg/mL) for the treatment of bipolar disorder is sufficient for the epigenetic effect to take place. Similar to propranolol,\textsuperscript{28} intermittent administration of valproate immediately before a psychological intervention is not suitable for clinical application in anxiety disorders. A single intravenous infusion (valproate 30 mg/kg/day) for 60 minutes takes 2–4 hours to reach the peak serum concentration, and a robust HDAC2 inhibition effect (in peripheral lymphocytes) is apparent from 6 to 48 hours after injection according to the results from a phase I clinical trial (valproate adjuvant therapy for chemotherapy for refractory cancer).\textsuperscript{47} At least 2 hours after injection seems to be required for HDAC inhibition to take an effect according to in vitro and in vivo preclinical studies.\textsuperscript{84,89}

Rapid titration of oral valproate (divalproex sodium) and its maintenance during intensive psychiatric interventions will be adequate for most clinical studies. For the absolute pitch training experiment, valproate ER 500 mg for 3 days and then 1,000 mg for 11 days (total 14 days) during training was used.\textsuperscript{71} Valproate 750–1,000 mg was a good starting point. Monitoring the serum valproic acid level could be helpful to adjust the individualized dosage and to check compliance.

The duration of valproate prescription after CBT termination is another question to be investigated. Case 1 received valproate at the start of CBT, and valproate was not discont
ued after the termination of CBT for the maintenance treatment of bipolar disorder. Case 2 had already received 300 mg of valproate three years before CBT, and valproate was continued after the termination of CBT. Case 3 was not prescribed valproate before CBT; valproate had been prescribed transiently combined with CBT and was discontinued after the termination of CBT with maintenance treatment of quetiapine and lithium (valproate combined with CBT). If a patient was already on effective maintenance treatment other than valproate, transient use of valproate during CBT could be an option, as in case 3 (Figure 1). If a patient received valproate as a maintenance treatment, a combination of CBT and ongoing valproate after CBT would be rational. Whether transient use of valproate combined with CBT (case 3) would be better than the maintenance of valproate after combined therapy (case 1) or chronic valproate therapy combined with CBT (case 2) remains to be answered.

The same issue has been debated in combined therapy of pharmacotherapy and CBT for anxiety disorders. Concurrent anxiolytics such as benzodiazepines have been associated with reduced long-term outcomes of CBT in anxiety disorders. Dose-dependent suppression of cortisol by benzodiazepines is partially responsible for the decreased effect of CBT. Cortisol release following emotional arousal, which occurs during CBT, is known to facilitate extinction learning and exposure-based therapy. Antidepressant and CBT combination therapy showed beneficial clinical effects compared to CBT or antidepressants alone in the long-term follow-up of antidepressant treatment. However, the beneficial effects of combined therapy appear to disappear after antidepressant discontinuation. According to state-dependent learning theory, taking antidepressants acts as a context, and the behavior learned during antidepressant treatment is not recalled well in an environment where an antidepressant is discontinued. Avoiding safety signals during exposure therapy is in the same vein. Without a safety signal, patients re-experience anxiety because they learn from exposure-based therapy that they are safe while the safety signal is present.

CONCLUSION AND FUTURE DIRECTION

In conclusion, patients with bipolar disorder, comorbid panic disorder, and/or agoraphobia may respond to CBT combined with valproate therapy. CBT should be considered, especially in patients with panic disorder who do not respond to antidepressant treatment. In the future, an open-label or placebo-controlled randomized controlled study is needed to confirm this approach to enhance the efficacy of CBT. If the limited use of valproate during CBT is effective in terms of having lasting effects on anxiety symptoms, the use of valproate in combination with CBT may also be applicable to patients with panic disorder in general.

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The author has no potential conflicts of interest to disclose.

ORCID iD
Kwang-Yeon Choi https://orcid.org/0000-0001-7134-8723

Funding Statement

This work was supported by the National Research Foundation of Korea (NRF) (NRF-2019M3E5D1A02068548).

REFERENCES

1. Yapici Eser H, Kacar AS, Kilciksiz CM, Yalçınay-Inan M, Ongur D. Prevalence and associated features of anxiety disorder comorbidity in bipolar disorder: a meta-analysis and meta-regression study. Front Psychiatry 2018;9:229.
2. Preti A, Vrublevska J, Veroniki AA, Huedo-Medina TB, Kyriazis O, Fountoulakis KN. Prevalence and treatment of panic disorder in bipolar disorder: systematic review and meta-analysis. Evid Based Ment Health 2018;21:53-60.
3. Frank E, Cyranowski JM, Rucci P, Shear MK, Fagiolini A, Thase ME, et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry 2002;59:905-911.
4. Simon NM, Otto MW, Wisniewski SR, Fossey M, Saghdyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 2004;161:2222-2229.
5. Gao K, Chan PK, Verduin ML, Kemp DE, Tolliver BK, Ganoocy SJ, et al. Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders. Am J Addict 2010;19:440-449.
6. Coryell W, Solomon DA, Fiedorowicz JG, Endicott J, Schetter PJ, Judd LL. Anxiety and outcome in bipolar disorder. Am J Psychiatry 2009;166:1238-1243.
7. Simon NM, Otto MW, Fischmann D, Racette S, Nierenberg AA, Pollow MH, et al. Panic disorder and bipolar disorder: anxiety sensitivity as a potential mediator of panic during manic states. J Affect Disord 2005;87:101-105.
8. Päären A, Bohman H, von Knorring L, Olsson G, von Knorring AL, Jonsson U. Early risk factors for adult bipolar disorder in adolescents with mood disorders: a 15-year follow-up of a community sample. BMC Psychiatry 2014;14:363.
9. Doughty CJ, Wells JE, Joyce PR, Olds Rj, Walsh AE. Bipolar-panic disorder comorbidity within bipolar disorder families: a study of siblings. Bipolar Disord 2004;6:245-252.
10. MacKinnon DF, Zandi PP, Cooper J, Potash JB, Simpson SG, Gershon E, et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002;159:30-35.
11. Hibar DP, Westlye LT, van Erp TG, Rasmussen J, Leonardo CD, Fasikowski J, et al. Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry 2016;21:1710-1716.
12. Altshuler L, Bookheimer S, Townsend J, Proenza MA, Sabb F, Mintz J,
et al. Regional brain changes in bipolar I depression: a functional magnetic resonance imaging study. Bipolar Disord 2008;10:708-717.
13. Kim JE, Dager SR, Lyoo IK. The role of the amygdala in the pathophysiology of panic disorder: evidence from neuroimaging studies. Biol Mood Anxiety Disord 2012;2:20.
14. Goldward AW. The neurobiology of panic: a chronic stress disorder. Chronic Stress (Thousand Oaks) 2017;1:247054701736038.
15. Dresler T, Guhn A, Tupalik SV, Ehls AC, Herrmann MJ, Fallgatter AJ, et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm (Vienna) 2012;120:3-29.
16. Womer FY, Kalmar JH, Wang F, Blumberg HP. A ventral prefrontal-amygdala neural system in bipolar disorder: a view from neuroimaging research. Acta Neuropsychiatr 2009;21:228-238.
17. Eden AS, Schreiber J, Anwander A, Keuper K, Laeger I, Zwaninger P, et al. Emotion regulation and trait anxiety are predicted by the microstructure of fibers between amygdala and prefrontal cortex. J Neurosci 2015;35:6020-6027.
18. Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beau lieu S, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 2012;24:46-22.
19. Mitchell JD, Brown ES, Rush AJ. Comorbid disorders in patients with bipolar and comorbid substance dependence. J Affect Disord 2007;102:281-287.
20. Goldberg JF, Nierenberg AA, Iosifescu DV. Wandering with antidepressant use in bipolar disorder: the ongoing debate. J Clin Psychiatry 2021;82:94ac13181.
21. Niitsu T, Fabbri C, Serretti A. Predictors of switch from depression to mania in bipolar disorder. J Psychiatr Res 2015;66:67-45:53.
22. Giffin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord 2018;6:25.
23. Ott CA. Treatment of anxiety disorders in patients with comorbid bipolar disorder. Ment Health Clin 2018;8:256-263.
24. Barlow DH. Cognitive-behavioral therapy for panic disorder: current status. J Clin Psychiatry 1997;58 Suppl 2:3:36; discussion 36-37.
25. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008;69:621-632.
26. Acheson DT, Forsyth JP, Prenoveau JM, Bouton ME. Interoceptive fear conditioning as a learning model of panic disorder: an experimental evaluation using 20% CO(2)-enriched air in a non-clinical sample. Behav Res Ther 2007;45:2280-2294.
27. Pappens M, Vandenbossche E, Van den Bergh O, Van Dieten I. Interoceptive fear learning to mild breathlessness as a laboratory model for unexpected panic attacks. Front Psychol 2015;6:1130.
28. Brunet A, Saumier A, Lyoo IK. The role of the amygdala in the pathophysiology of panic disorder: evidence from neuroimaging studies. Biol Mood Anxiety Disord 2012;2:20.
29. Goddard AW. The neurobiology of panic: a chronic stress disorder. Chronic Stress (Thousand Oaks) 2017;1:247054701736038.
30. Dresler T, Guhn A, Tupalik SV, Ehls AGC, Herrmann MJ, Fallgatter AJ, et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm (Vienna) 2012;120:3-29.
31. Womer FY, Kalmar JH, Wang F, Blumberg HP. A ventral prefrontal-amygdala neural system in bipolar disorder: a view from neuroimaging research. Acta Neuropsychiatr 2009;21:228-238.
32. Eden AS, Schreiber J, Anwander A, Keuper K, Laeger I, Zwaninger P, et al. Emotion regulation and trait anxiety are predicted by the microstructure of fibers between amygdala and prefrontal cortex. J Neurosci 2015;35:6020-6027.
33. Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beau lieu S, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 2012;24:46-22.
34. Mitchell JD, Brown ES, Rush AJ. Comorbid disorders in patients with bipolar and comorbid substance dependence. J Affect Disord 2007;102:281-287.
35. Primeau F, Fontaine R, Beaucclair L. Valproic acid and panic disorder. Can J Psychiatry 1990;35:248-250.
36. Keck PE Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993;33:542-546.
37. Perugi G, Frare F, Toni C, Tusini G, Vannucci G, Akiskal HS. Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year “open” follow-up study. Eur Arch Psychiatry Clin Neurosci 2010;260:553-560.
38. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998;43:73-77.
39. Katzman MA, Bleau P, Blier P, Chodda P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14 Suppl 1:5.
40. Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwot O, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry 2018;52:1109-1172.
41. NICE. Generalised anxiety disorder and panic disorder in adults: management (CG113). Available at: https://www.nice.org.uk/guidance/cg113. Accessed April 20, 2022.
42. Winterer G. Valproate and GABAergic system effects. Neuropsychopharmacology 2003;28:2050-2051.
43. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009;459:55-60.
44. Heinrichs SC, Leite-Morris KA, Rasmussen AM, Kaplan GR. Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci Lett 2013;552:108-113.
45. Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn Mem 2008;15:39-45.
46. Gräff J, Joseph NF, Horn ME, Samiel A, Meng J, Seo J, et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 2014;156:261-276.
47. Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol 2021;87:5477-5479.
48. Shin J, Park DH, Ryu SH, Ha JH, Kim SM, Jeon HJ. Clinical implications of agoraphobia in patients with panic disorder. Medicine (Baltimore) 2020;99:e21414.
49. Spoorthy MS, Chakrabarti S, Grover S. Comorbidity of bipolar and anxiety disorders: an overview of trends in research. World J Psychiatry 2019;9:7-29.
50. Choi KY, Kim YK. Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016;70:134-147.
51. Alberini CM, Kandel ER. The regulation of transcription in memory research. Acta Neuropsychiatr 2009;21:228-238.
52. Heinrichs SC, Leite-Morris KA, Rasmussen AM, Kaplan GR. Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci Lett 2013;552:108-113.
53. Bredy TW, Barad M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn Mem 2008;15:39-45.
54. Gräff J, Joseph NF, Horn ME, Samiel A, Meng J, Seo J, et al. Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 2014;156:261-276.
55. Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol 2021;87:5477-5479.
56. Shin J, Park DH, Ryu SH, Ha JH, Kim SM, Jeon HJ. Clinical implications of agoraphobia in patients with panic disorder. Medicine (Baltimore) 2020;99:e21414.
Valproate Adjuvant Cognitive Behavioral Therapy

dation. Neurosci Biobehav Rev 2016;71:48-57.
55. Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry 2006;12:120-150.
56. Gogolla N, Carone P, Lüthi A, Henry C. Perineuronal nets protect fear memories from erasure. Science 2009;325:1258-1261.
57. Monfils MH, Cowansage KK, Klann E, LeDoux JE. Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories. Science 2009;324:951-955.
58. Nader K, Hardt O. A single standard for memory: the case for reconsolidation. Nat Rev Neurosci 2009;10:224-234.
59. Schiller D, Monfils MH, Raio CM, Johnson DC, Ledoux JE, Phelps EA. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2010;463:49-53.
60. Agren T, Engman J, Frick A, Björkstrand J, Larsson EM, Furmark T, et al. Disruption of reconsolidation erases a fear memory trace in the human amygdala. Science 2012;337:1550-1552.
61. Björkstrand J, Agren T, Frick A, Engman J, Larsson EM, Furmark T, et al. Disruption of memory reconsolidation erases a fear memory trace in the human amygdala: an 18-month follow-up. PLoS One 2015;10:e0129393.
62. Costanzi M, Cannas S, Saraulli D, Rossi-Arnaud C, Cestari V. Extinction after retrieval: effects on the associative and nonassociative components of remote contextual fear memory. Learn Mem 2011;18:508-518.
63. Asthana MK, Brunhuber B, Mühlberger A, Reif A, Schneider S, Hermann MJ. Preventing the return of fear using reconsolidation update mechanisms depends on the Met-allele of the brain derived neurotrophic factor Val66Met polymorphism. Int J Neuropsychopharmacol 2016;19:pyv137.
64. Rao-Buiz P, Visser E, Mitric M, Smit AB, van den Oever MC. A synaptic framework for the persistence of memory engrams. Front Synaptic Neurosci 2021;13:661476.
65. Lepow L, Morishita H, Yehuda R. Critical period plasticity as a framework for psychedelic-assisted psychotherapy. Front Neurosci 2021;15:71004.
66. Nabel EM, Morishita H. Regulating critical period plasticity: insight from the visual system to fear circuitry for therapeutic interventions. Front Psychiatry 2013;4:146.
67. Greico SF, Qiao X, Zheng X, Liu Y, Chen L, Zhang H, et al. Subanesthetic ketamine reactivates adult cortical plasticity to restore vision from amblyopia. Curr Biol 2020;30:3591-3603.e8.
68. Maya Vetencourt JF, Sale A, Viegia A, Barocelli L, De Pasquale R, O’Leary PJ, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008;320:385-388.
69. Not A, Cho S, Lee JH. HDAC2 expression in parvalbumin interneurons regulates synaptic plasticity in the mouse visual cortex. Neurogenetics 2015;1:34-40.
70. Silingardi D, Scali M, Belluomini G, Pizzorusso T. Epigenetic treatments of adult rats promote recovery from visual acuity deficits induced by long-term monocular deprivation. Eur J Neurosci 2010;31:2185-2192.
71. Gervain J, Vines BW, Chen LM, Seo BJ, Hensch TK, Werker JF, et al. Valproate reopens critical-period learning of absolute pitch. Front Syst Neurosci 2013;7:102.
72. Wakiizono T, Nakashima H, Yasui T, Noda T, Aoyagi K, Okada K, et al. Growth factors with valproic acid restore injury-impaired hearing by promoting neuronal regeneration. JCI Insight 2021;6:e139171.
73. Bach DR, Korn CW, Vunder J, Bantel A. Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial. Transl Psychiatry 2018;8:157.
74. Aliyev NA, Aliyev ZN. Valproate (depamine-chromes) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008;23:109-114.
75. Kang H. Critical consideration on Korean supreme court’s criteria for separating clinical trials from individual medical practices. Seoul Law Journal 2013;54:185-217.
76. Lee IH, Seo M, Lee YS, Rye S, Kim H, Lee S. Development of regulation system for off-label drug use. Yakhak Hoeji 2014;58:112-124.
77. Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003;18:169-172.
78. de Angelis L. Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. Pharmacol Biochem Behav 1995;52:329-333.
79. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021;78:481-489.
80. Mitchell JM, Bogenschütz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021;27:1025-1033.
81. Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry 2020;10:206.
82. Reinstatter L, Yousef NA. Ketamine as a potential treatment for suicide ideation: a systematic review of the literature. Drugs R D 2015;15:37-43.
83. de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep 2021;37:109836.
84. de Vos CMH, Mason NL, Kuyper PS. Psychodetics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychodetics. Front Psychiatry 2021;12:74606.
85. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Foc (Am Psychiatr Publ) 2021;19:95-115.
86. Götlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
87. Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, et al. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 2007;97:177-182.
88. Killick-Cole CL, Singleton WGB, Bienemann AS, Asby DJ, Wyatt MJ, Boulter LJ, et al. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. PLoS One 2017;12:e0176855.
89. Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, et al. An epigenetic mouse model for molecular and behavioral neuropsychopathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A 2002;99:17095-17100.
90. Foa EB, Franklin MF, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 2002;52:987-997.
91. Otto MW, McHugh RK, Kantak KM. Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes. Clin Psychol (New York) 2010;17:91-103.
92. Westra HA, Stewart SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anxiety Disord 2002;16:233-246.
93. Marks IM, Swinson RP, Başoğlu M, Kuch K, Noshirvan H, O’Sullivan G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993;162:776-787.
94. Pomara N, Willoughby LM, Siddis JJ, Cooper TB, Greenblatt DJ. Cortisol response to dexamethas: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacology (Berl) 2004;178:1-8.
95. de Quervain D, Wolf OT, Roozenaal B. Glucocorticoid-induced en-
hancement of extinction-from animal models to clinical trials. Psychopharmacology (Berl) 2019;236:183-199.

96. van Apeldoorn FJ, van Hout WJ, Mersch PP, Huisman M, Slaap BR, Hale WW 3rd, et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand 2008;117:260-270.

97. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000;283:2529-2536.

98. Coupland NJ. Combined antidepressants and CBT for panic disorder with agoraphobia. J Psychiatry Neurosci 2008;33:176.